Risa M Hoffman, Konstantia Nadia Angelidou, Sean S Brummel, Friday Saidi, Avy Violari, Dingase Dula, Vidya Mave, Lee Fairlie, Gerhard Theron, Moreen Kamateeka, Tsungai Chipato, Benjamin H Chi, Lynda Stranix-Chibanda, Teacler Nematadzira, Dhayendre Moodley, Debika Bhattacharya, Amita Gupta, Anne Coletti, James A McIntyre, Karin L Klingman, Nahida Chakhtoura, David E Shapiro, Mary Glenn Fowler, Judith S Currier
BACKGROUND: IMPAACT PROMISE 1077BF/FF was a randomized study of antiretroviral therapy (ART) strategies for pregnant and postpartum women with high CD4+ T-cell counts. We describe postpartum outcomes for women in the study who were randomized to continue or discontinue ART after delivery. METHODS: Women with pre-ART CD4+ cell counts ≥350 cells/mm3 who started ART during pregnancy were randomized postpartum to continue or discontinue treatment. Women were enrolled from India, Malawi, South Africa, Tanzania, Uganda, Zambia, and Zimbabwe...
December 2018: HIV Clinical Trials